Medclair (MCLR) investor relations material

Executive summary

• Order intake for Q2 2026 reached 25.1 MSEK, nearly doubling compared to Q2 2025, supporting future growth.

• Net sales for Q2 2026 were 14.3 MSEK, with H1 2026 net sales totaling 32.5 MSEK.

• Book-to-bill ratio for Q2 2026 stood at 1.76, indicating robust demand.

• EBITDA for H1 2026 was SEK 6.3 million, down from SEK 10.0 million in H1 2025, reflecting increased investments in international expansion.

• International expansion included new markets in Singapore and New Zealand, positioning for continued growth.

Financial highlights

• H1 2026 order intake was SEK 41.2 million, up from SEK 34.7 million in H1 2025.

• H1 2026 net sales reached SEK 32.5 million, a slight increase from SEK 31.4 million in H1 2025.

• Book-to-bill ratio for Q2 2026 was 1.76, up from 0.80 in Q2 2025.

• Cash and cash equivalents at period end were SEK 18.9 million, up from SEK 1.3 million in June 2025.

• Profit after tax for H1 2026 was SEK 3.3 million, with a Q2 2026 loss after tax of SEK -0.4 million.

Outlook and guidance

• Full-year sales are expected to exceed 2025 levels, supported by a strong order book and positive Q3 start.

• Continued global expansion strategy with operations in over 20 countries.

• Diversification across healthcare, dental, and industrial segments supports multiple growth paths.

• Favorable long-term market conditions driven by regulatory and sustainability trends.

• Continued investments in commercial scale-up, patent protection, and new product platforms.